I-Mab looks to fill gap in NASDAQ listings by Chinese players

I-Mab Biopharma is hoping to become only the second innovative Chinese drug developer since Zai two years ago to go public on NASDAQ.

The Shanghai-based company has proposed to raise up to $100 million in an offering underwritten by Jefferies, CICC, China Renaissance and Huatai Securities...